For the year ending 2025-12-31, PLX has $82,346K in assets. $34,116K in debts. $14,680K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 14,680 | |||
| Short-term bank deposits | 15,593 | |||
| Restricted deposit | 702 | |||
| Accounts receivable | 8,840 | |||
| Other assets | 1,129 | |||
| Inventories | 25,729 | |||
| Total current assets | 66,673 | |||
| Funds in respect of employee rights upon retirement | 578 | |||
| Property and equipment, net | 4,879 | |||
| Deferred income tax asset | 2,516 | |||
| Operating lease right of use assets | 7,700 | |||
| Total assets | 82,346 | |||
| Trade | 5,259 | |||
| Other | 19,875 | |||
| Operating lease liabilities | 1,384 | |||
| Total current liabilities | 26,518 | |||
| Liability for employee rights upon retirement | 661 | |||
| Operating lease liabilities | 6,937 | |||
| Total long term liabilities | 7,598 | |||
| Total liabilities | 34,116 | |||
| Common stock, 0.001 par value authorized - as of december 31, 2024 and 2025, 185,000,000 shares issued and outstanding - as of december 31, 2024 and 2025, 75,850,275 and 80,425,981 shares, respectively | 80 | |||
| Additional paid-in capital | 433,147 | |||
| Accumulated deficit | -384,997 | |||
| Total stockholders' equity | 48,230 | |||
| Total liabilities and stockholders' equity | 82,346 | |||
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)